ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC
- HS-20117 has demonstrated a promising anti-tumor activity in advanced NSCLC harboring EGFR ex20ins mutation with the mPFS 9.6 months and mDoR 16.6 months.
SHANGHAI, June 17, 2026— Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharma,” 03692.HK) today announced that the encouraging results from the HS-20117 (EGFR/c-MET bispecific) for the treatment of platinum-pretreated EGFR Exon20ins-mutated advanced non-small cell lung cancer (NSCLC) were orally presented in the Proffered Paper session at ESMO TAT ASIA 2026 (June 12-14, Hong Kong, China).
HS-20117 is a fully human immunoglobulin G1(IgG1)-like bispecific antibody targeting both EGFR and c-MET, which is under clinical development for patients with NSCLC, colorectal cancer and head and neck squamous cell carcinoma, etc. At ESMO TAT ASIA 2026, the presented data were generated from HS-20117-101 (NCT05940116), which is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors. The leading principal investigator of this study is Professor Dingzhi Huang, (Vice President of Tianjin Cancer Hospital).
The study results showed:
● Promising Efficacy：Among 22 efficacy-evaluable patients with EGFR Exon20ins-mutated advanced NSCLC treated with HS-20117, the median duration of response was 16.6 months, the median progression-free survival was 9.3 months indicating encouraging and durable response, and the estimated 12-month overall survival rate was 84.9% showed promising survival benefit.
● Manageable Safety: Among 25 safety-evaluable patients, HS-20117 demonstrated a favorable and manageable safety profile, with most Treatment-Related Adverse Events (TRAEs) being Grade 1-2. Only 6 patients experienced Grade 3 TRAEs. No grade 4 or 5 TRAEs were reported. No TRAE led to dose discontinuation or death.
These findings contribute to the broader understanding and potential value of HS-10382 in patients with newly diagnosed Ph+ CML-CP.
Details of the oral presentation are as follows:
◆ Poster Title: HS-20117 (EGFR/c-MET Bispecific Antibody) in EGFR Exon 20 Insertion–Mutated Non–Small Cell Lung Cancer After Platinum Based Chemotherapy: Results from a Phase I Study
◆ Session: Proffered Paper session
◆ Abstract No.: 1O
◆ Date/Time: 11:45-13:00, Sat, June 13, 2026
◆ Presenter: Dr. Sizhe Yu, Zhejiang cancer hospital, Hangzhou, China
About HS-20117
HS-20117 is a fully human immunoglobulin IgG1-like bispecific antibody targeting EGFR and c-MET.
HS-20117 binds both targets concurrently and produces anti-tumor effects by blocking EGFR/c-MET signaling and inducing antibody-dependent cellular cytotoxicity (ADCC).
In November 2022, Hansoh Pharma entered into an exclusive licensing agreement with Biotheus Biotechnology (Zhuhai) Co., Ltd. (“Biotheus”, acquired by BioNTech in 2025) for the development and commercialization of HS-20117 in Greater China, including the Chinese Mainland, Hong Kong, Macau, and Taiwan.
About NSCLC
EGFR exon 20 insertion is the third most common EGFR mutation in NSCLC [1,2]. Unlike classic sensitizing mutations, exon 20 insertions are intrinsically resistant to conventional EGFR TKIs, because it is defined by an altered active site that sterically hinders TKI binding. After platinum-based chemotherapy failure, these patients have very limited treatment options and poor clinical outcomes, representing a major unmet medical need in thoracic oncology.
References
1. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol 2018;13(10):1560-1568. doi:10.1016/j.jtho.2018.06.019.
2. Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 2019;4:5. 10.1038/s41392-019-0038-9 Abbreviations: EGFR: epidermal growth factor receptor; Exon20ins: Exon 20 Insertion; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
